Mark Avigan, MD, CM, FAASLD

Biography

As a hepatologist and Associate Director in CDER's Office of Pharmacovigilance and Epidemiology, Dr. Avigan has served as an expert consultant at FDA for the evaluation of drug-induced liver injury during the life cycle of drugs and biological agents. Earlier on, Dr. Avigan received his MD from McGill University. After his medical residency and GI fellowship, he trained as an NIH staff fellow and then was on the faculty of Georgetown University where he attended patients and was the principal investigator of NIH-funded grants to elucidate basic mechanisms in cell growth pathways. With earlier service in CDER as a division director in the field of drug safety, Dr. Avigan has authored or co-authored close to 180 scientific publications, book chapters and professional meeting abstracts. Dr. Avigan participates in public-private partnerships supporting innovation in the analysis of hepatotoxicity associated with pharmaceuticals and biological agents.